Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 9/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159388 | 0.89 | PIM1 (0.36) | PIM1PIM3PIM2EGFRHTR1D | |
| SCHEMBL4159498 | 0.88 | PDPK1 (0.39) | S1PR1HPGDCYP2C19DYRK1A | |
| SCHEMBL4174413 | 0.84 | PIM1 (0.41) | PIM1PIM3PIM2TLR9TLR8 | |
| Formic Acid SCHEMBL4160207 | 0.84 | AURKA (0.41) | S1PR1HPGDCYP2C19 | |
| SCHEMBL3249166 | 0.83 | PIM1 (0.40) | PIM1PIM3PIM2TLR9TLR8 | |
| SCHEMBL4157705 | 0.82 | HPGD (0.41) | PIM1PIM3PIM2HPGDCYP2C19 | |
| Formic Acid SCHEMBL3249581 | 0.82 | JAK3 (0.36) | PIM1PIM3PIM2 | |
| Propionic Acid SCHEMBL4159389 | 0.81 | PIM1 (0.37) | PIM1PIM3PIM2TLR9TLR8 | |
| SCHEMBL4169945 | 0.80 | AURKA (0.43) | S1PR1HPGDCYP2C19 | |
| SCHEMBL4160172 | 0.79 | PDPK1 (0.43) | PIM1PIM2S1PR1HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | PIM1 279/4885PIM3 337/4885PIM2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.